Delayed-Release Dimethyl Fumarate Safety and Efficacy in Pediatric Patients With Relapsing-Remitting Multiple Sclerosis

Delayed-Release Dimethyl Fumarate Safety and Efficacy in Pediatric Patients With Relapsing-Remitting Multiple Sclerosis

Background: Pediatric multiple sclerosis (MS) is rare: only 1.5–5% of MS cases are diagnosed before 18 years of age, and data on disease-modifying therapies (DMTs) for pediatric MS are limited. The CONNECTED study assessed the long-term safety and efficacy of treatment with delayed-release dimethyl...

Full description

Bibliographic Details
Main Authors: Raed Alroughani, Peter Huppke, Maria Mazurkiewicz-Beldzinska, Astrid Blaschek, Martin Valis, Gregory Aaen, Joe Pultz, Xiaomei Peng, Vanessa Beynon
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-01-01
Series:Frontiers in Neurology
Subjects:
relapsing-remitting multiple sclerosis
dimethyl fumarate
safety
efficacy
pediatric
pharmacokinetics
Online Access:https://www.frontiersin.org/articles/10.3389/fneur.2020.606418/full

Internet

https://www.frontiersin.org/articles/10.3389/fneur.2020.606418/full

Similar Items